Conclusion
IMID patients had an attenuated response to the standard vaccination regimen compared with healthy controls. This study supports that these vaccines are safe in an immunosuppressed population, and it demonstrates that the frequency of reported adverse events was lower among IMID patients than among controls, with the same types of of adverse events reported in both groups. A third vaccine dose was safe and resulted in serologic response in most patients.
These data facilitate identification of patient groups at risk of an attenuated vaccine response, and they support administering a third vaccine dose to IMID patients with a weak serologic response to the standard regimen.
For full study details, including source material, refer to the full article.
Excerpted and adapted from:
Syversen SW, Jyssum I, Tveter AT, et al. Immunogenicity and safety of standard and third-dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy. Arthritis Rheumatol. 2022 Aug;74(8).
